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Abstract
Background: Growth of cancer cells results from the disturbance of positive and negative growth
control mechanisms and the prolonged survival of these genetically altered cells due to the failure
of cellular suicide programs. Genetic and biochemical approaches have identified Raf family serine/
threonine kinases B-Raf and C-Raf as major mediators of cell survival. C-Raf cooperates with Bcl-
2/Bcl-XL in suppression of apoptosis by a mechanism that involves targeting of C-Raf to the outer
mitochondrial membrane and inactivation of the pro-apoptotic protein Bad. However, apoptosis
suppression by C-Raf also occurs in cells lacking expression of Bad or Bcl-2.
Results: Here we show that even in the absence of Bcl-2/Bcl-XL, mitochondria-targeted C-Raf
inhibits cytochrome c release and caspase activation induced by growth factor withdrawal. To
clarify the mechanism of Bcl-2 independent survival control by C-Raf at the mitochondria a search
for novel mitochondrial targets was undertaken that identified voltage-dependent anion channel
(VDAC), a mitochondrial protein (porin) involved in exchange of metabolites for oxidative
phosphorylation. C-Raf forms a complex with VDAC in vivo and blocks reconstitution of VDAC
channels in planar bilayer membranes in vitro.
Conclusion: We propose that this interaction may be responsible for the Raf-induced inhibition
of cytochrome c release from mitochondria in growth factor starved cells. Moreover, C-Raf kinase-
induced VDAC inhibition may regulate the metabolic function of mitochondria and mediate the
switch to aerobic glycolysis that is common to cancer cells.
Background
Anti-apoptotic Bcl-2 family members are overexpressed in
a large number of cancers and are responsible for resist-
ance to anticancer drugs [1]. Oncogenic C-Raf contributes
to the processes of cellular transformation and tumor de-
velopment through its ability to suppress apoptotic cell
death. Experimental evidence has been obtained, showing
that C-Raf maintains cell survival by (i) induction of auto-
crine loops via the mitogenic cascade resulting in the acti-
vation of protein kinase B (PKB) [5,6], and (ii)
cooperation with Bcl-2, which targets C-Raf to mitochon-
dria and results in the inactivation of the pro-apoptotic
protein Bad [3,7,8]. Additionally, Raf may suppress apop-
tosis by activation of NF-κ B [9,10], and interaction with
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Figure 1
C-Raf modulates the mitochondrial membrane potential during apoptosis. A. Overexpression of C-Raf kinase in 32Dcl.3 cell lines.
32Dcl.3 cells expressing Mas-BXB fusion protein were maintained in IL3-containing medium. Expression of constitutively active
Mas-BXB and inactive Mas-BXB K375W proteins was detected in mitochondrial but not cytosolic fractions using an anti-C-Raf
antibody. Cell viability of 32Dcl.3 cell lines. 32Dcl.3 transfected cells were cultured without IL-3 for 24 hours and % viable cells
was determined by trypan dye-exclusion.BMC Cell Biology 2002, 3 http://www.biomedcentral.com/1471-2121/3/14
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IAP proteins (Sendtner, Troppmair and Rapp, unpub-
lished results). The anti-apoptotic Bcl-2 family members
expressed in the outer mitochondrial membrane inhibit
the release of apoptogenic cytochrome c from mitochon-
dria [11,12], antagonize the pore-forming activity of Bax
[13], and directly interact with the mitochondrial perme-
ability transition pore (PTP) that regulates mitochondrial
membrane potential [14,15]. C-Raf induces phosphoryla-
tion of Bad, which in turn leads to sequestration of Bad in
a complex with 14-3-3 in the cytosol [3,16]. However, C-
Raf also suppresses apoptosis in cells that do not express
Bad or are deficient for Bcl-2 [8] suggesting the existence
of other targets for C-Raf at the outer mitochondrial mem-
brane. Here we provide evidence that C-Raf regulates the
mitochondrial voltage-dependent anion channel (VDAC)
that can contribute to cell survival.
Results and Discussion
First we examined the effect of C-Raf on mitochondrial cy-
tochrome c release. For this we used the expression plas-
mid pcDNA3-Mas-BXB, in which constitutively active C-
Raf, BXB, was fused with the transmembrane domain of
the yeast outer mitochondrial membrane protein Mas
[17], allowing targeting of C-Raf to mitochondria inde-
pendently of Bcl-2 [3]. BXB, the mutant of Raf used, lacks
the N-terminal domain of C-Raf (residues 26–303) to pre-
vent interaction with the small G protein Ras at the plas-
ma membrane [18,19]. Upon transfection of interleukin 3
(IL-3) dependent 32Dcl.3 promyeloid cells, Mas-BXB was
detected by western blotting almost exclusively in the mi-
tochondrial fraction (Figure 1A). When deprived of IL-3
for 24 hours 32Dcl.3-Mas-BXB cells showed delayed cell
death (Figure 1B) compared to 32Dcl.3 cells expressing
the empty vector or a kinase dead version of mitochondri-
al Raf, Mas-BXB K375W, as previously shown [3]. IL-3
deprivation induced mitochondrial membrane depolari-
zation observed in 32Dcl.3-vector and 32Dcl.3-Mas-BXB
K375W cells is attenuated in 32Dcl.3-Mas-BXB cells and
almost completely suppressed in 32Dcl.3 overexpressing
Bcl-2 (Figure 2). These effects correlated with a partial
blockage of cytochrome c release from mitochondria (Fig-
ure 3) and inhibition of pro-caspases 3 and 9 cleavage in
32Dcl.3-Mas-BXB, but not in 32Dcl.3-Mas-BXB K375W or
vector transfected cells (Figure 3). Once in the cytoplasm
cytochrome c binds with ATP to Apaf-1, which recruits
and activates pro-caspase 9 [20]. Caspase 9 subsequently
induces caspase 3 activation, which triggers the execution
of apoptotic cell death. Taken together these data suggest
that C-Raf inhibits apoptosis through mitochondrial
membrane potential (∆Ψ m) stabilization and inhibition
of cytochrome c release.
VDAC, which is the most abundant protein of the outer
mitochondrial membrane, provides a major channel for
the movement of ions, ADP/ATP and metabolites in and
out of mitochondria [21]. It is a core component of the
permeability transition pore (PTP) [21,22]. Opening of
the PTP causes ∆Ψ m disruption [22–24] and release of cy-
tochrome c, most likely through VDAC/Bax channels
[15,25,26]. Bcl-2 induces closure of these channels, there-
by inhibiting the release of cytochrome c and ∆Ψ m loss.
To examine a potential interaction of C-Raf with cyto-
chrome c releasing channels we first examined binding of
C-Raf to Bax. Binding studies and the analysis of Bax
phosphorylation in cotransfected 293 cells gave negative
results (data not shown). The situation was different when
VDAC was used instead of Bax. For this, constitutively ac-
tive C-Raf (C-RafDD) and hemagglutinin-tagged VDAC
(HA-VDAC) were transiently transfected into 293 cells
and immunoprecipitation was performed 48 hours later
using anti-C-Raf or anti-HA-antibody. C-Raf and VDAC
coimmunoprecipitated from doubly transfected cells (Fig-
ure 4). Coimmunoprecipitation was also detected with
cells coexpressing kinase inactive form of C-Raf together
with HA-VDAC (data not shown), demonstrating that C-
Raf kinase activity is not required for the interaction with
VDAC. To narrow down the region of C-Raf binding to
VDAC, HA-VDAC and the C-terminal half of C-Raf, BXB,
were coexpressed in 293 cells. BXB and HA-VDAC were
present in pull down experiments with either HA or C-Raf
antibody, suggesting that the C-terminal part of C-Raf is
sufficient for binding of VDAC (Figure 4). No interaction
was detected between VDAC and the regulatory N-termi-
nal part of C-Raf (data not shown).
After identifying VDAC as a new binding partner of C-Raf,
we investigated, whether VDAC was phosphorylated by C-
Raf. HA-VDAC immunoprecipitated from 293 cells was
not phosphorylated in an in vitro kinase assay (Figure 5A),
neither by recombinant full length active C-Raf (GST-C-
RafDD) protein nor by the active recombinant C-terminal
domain of C-Raf containing the catalytic region (BXB-
DD), whereas both active kinases, but not inactive (GST-
C-RafK375W) C-Raf, were able to phosphorylate MEK. To
exclude indirect phosphorylation of VDAC by C-Raf in vi-
vo, active C-Raf (C-RafDD or BXB) or the mitochondrial
membrane targeted constitutively active Mas-BXB were
cotransfected with VDAC into 293 cells. No phosphoryla-
tion of HA-VDAC was observed (Figure 5B), whereas Mas-
BXB induced phosphorylation of HA-Bad as previously
described [3]. We conclude that C-Raf binding does not
induce phosphorylation of this mitochondrial protein.
To test for functional consequences of this interaction we
examined the effect of C-Raf on VDAC channel activity.
When reconstituted in a planar lipid bilayer membrane
purified rat liver VDAC protein forms voltage-dependent
and large conductance ion channels (1 nS in 0.3 M KCl)
(Figure 6A). Rat liver VDAC protein was pre-incubated
with recombinant GST-C-Raf or GST proteins before ana-BMC Cell Biology 2002, 3 http://www.biomedcentral.com/1471-2121/3/14
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Figure 2
C-Raf delays the mitochondrial membrane depolarization occurring during apoptosis. 32Dcl.3 transfected cells were cultured with or
without IL-3 for 24 hours, incubated with JC-1 cationic dye and washed with PBS before flow cytometry.BMC Cell Biology 2002, 3 http://www.biomedcentral.com/1471-2121/3/14
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lysing the VDAC channel activity. Recombinant active C-
Raf protein (GST-C-RafDD) abolished the channel activi-
ty whereas GST or the inactive form of C-Raf (GST-C-
RafK375W) (Figure 6A) or wild type protein (data not
shown) had no effect. Inhibition of VDAC channel activi-
ty by C-Raf was specific since GST-C-RafDD did not alter
the properties of Bcl-2 pores (Figure 6B). Moreover, the
anti-apoptotic PAK1 kinase (active His-PAK1-T423E en-
zyme) and the MAPK pathway activating Src family kinase
Lck (His-LckY505F kinase) did not modify the VDAC
channel conductance (Figure 7). The interaction between
VDAC and C-Raf is not sufficient for inhibition of channel
activity since kinase dead C-Raf bound but did not inhibit
VDAC. To check if C-Raf closed the VDAC channel or in-
hibited its reconstitution into the membranes, active or
inactive C-Raf was added in lipid bilayer experiments to
preformed rat liver VDAC channels. In these experiments
active C-Raf had no effect on already existing VDAC but
blocked further reconstitution presumably by opposing
membrane insertion (Figure 8). Stimulation of C-Raf ki-
nase activity is paralleled by autophosphorylation, regula-
tory (S338, Y340/341) as well as feedback
phosphorylation (multiple S/T phosphorylation sites)
[27]. A negative net charge resulting from autophosphor-
ylation (seen in the in vitro kinase assay, Figure 5A) and
the presence of negatively charged glutamic acids in the
mutant GST-C-RafDD protein (YY340/341-DD) might be
the basis for the inhibitory effect of C-Raf on VDAC in
contrast to inactive GST-C-Raf, which possesses near neu-
tral charge. The negatively charged form of C-Raf may
bind to the N-terminal amphipatic α -helix of VDAC and
induce a conformational change of the channel. The C-
Raf-VDAC dimer may no longer be able to insert into the
membrane in an analogous fashion to the binding of an-
Figure 3
C-Raf inhibits the release of cytochrome c from mitochondria and caspases processing. 32Dcl.3 transfected cells were maintained
without IL-3 for different time periods before isolating mitochondria and cytosol. Immunoblot analysis was performed on mito-
chondrial extracts for the detection of cytochrome c release and on cytosol for the analysis of procaspases 3 and 9 cleavage.
Blots were stripped and reprobed with anti-VDAC or anti-actin antibodies as protein loading control.BMC Cell Biology 2002, 3 http://www.biomedcentral.com/1471-2121/3/14
Page 6 of 12
(page number not for citation purposes)
tibodies to VDAC [28,29]. Binding of active C-Raf kinase
to VDAC may thus block cytochrome c release and apop-
tosis by decreasing the number of channels in the outer
mitochondrial membrane. C-Raf shares with Bcl-2
[30,31] the ability to bind to VDAC and suppress cyto-
chrome c release albeit by different mechanism, pore re-
duction versus pore closure. C-Raf and Bcl-2 could
cooperate to directly block the VDAC protein inhibiting
the VDAC-induced depolarization and preventing func-
tional PTP formation during apoptosis. Moreover, as reg-
ulation of respiration and cell survival [32] are coupled we
cannot exclude the possibility of additional targets for C-
Raf such as VDAC-bound oxidative phosphorylation- or
glycolysis-enzymes. Our data, together with those show-
Figure 4
C-Raf interacts with VDAC. C-Raf and HA-VDAC proteins were transiently coexpressed in 293 cells and immunoprecipitated
with anti-C-Raf (A) or anti-HA antibodies (B) before SDS-PAGE analysis. Immunoblot were probed with anti-C-Raf or anti-HA
antibodies.BMC Cell Biology 2002, 3 http://www.biomedcentral.com/1471-2121/3/14
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Figure 5
C-Raf kinase does not phosphorylate VDAC protein. A. In vitro kinase assay was performed using GST-C-Raf recombinant protein
and HA-VDAC immunoprecipitated from 293 cells. HA-VDAC was incubated with recombinant active or inactive GST-C-Raf
proteins in presence of radioactive ATP. As a positive control GST-C-Raf was incubated with MEK kinase dead substrate in the
same conditions. The blots were also probed with anti-HA and anti-C-Raf antibodies. B. In vivo phospholabelling was performed
by coexpressing HA-VDAC with different C-Raf constructs in 293 cells. Transfected cells were incubated with radioactive
orthophosphate before HA-VDAC immunoprecipitation. HA-Bad was used as a positive control.BMC Cell Biology 2002, 3 http://www.biomedcentral.com/1471-2121/3/14
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ing an involvement of A-Raf in controlling glycolysis (sub-
mitted data) provide evidence that Raf kinases are
involved in mitochondrial function and regulation of cell
metabolism, which might be an essential feature of their
oncogenic potency.
Conclusions
C-Raf has been demonstrated previously to interact with
members of the Bcl-2 family that regulate traffic of apop-
togenic proteins through the outer mitochondrial mem-
brane. Here we identify the outer mitochondrial channel
protein VDAC as binding partner and effector of C-Raf.
We propose that this interaction may be responsible for
the Raf-induced inhibition of cytochrome c release. More-
over, C-Raf kinase-induced VDAC inhibition may regulate
the metabolic function of mitochondria and mediate the
switch to aerobic glycolysis that is common to cancer
cells.
Materials and Methods
Plasmids
Human Bcl-2 cDNA encoding a protein lacking the
COOH-terminal transmembrane domain (TM) (Bcl-
2∆ C21: residues 219–239 in Bcl-2). cDNA coding for
GST-Bcl-2∆ Tm was expressed in pGEX-4T1 plasmid (gift
of J. Reed). GST-C-RafYY340/341DD (active form of Raf),
GST-C-RafK375W (inactive form of C-Raf), His-PAK1-
T423E and His-LckY505F were cloned in pFastBac baculo-
viruses for expression in Sf9 insect cells.
Figure 6
C-Raf kinase inhibits the VDAC channel function. Single channel recordings of purified rat liver VDAC protein in a DiphPC mem-
brane. VDAC or Bcl-2∆ Tm were preincubated with active GST-C-RafDD, inactive GST-C-RafK375W, or GST recombinant
proteins before channel conductance measurement (A, B).BMC Cell Biology 2002, 3 http://www.biomedcentral.com/1471-2121/3/14
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Human VDAC1 cDNA was released from the pSK plasmid
by BamHI and SalI restriction enzymes and subcloned
into the BamHI/EcoRV sites of pTracer-CMV plasmid to
produce a HA-tag fusion protein. cDNAs coding for Mas-
BXB, BXB or C-Raf were expressed in the pcDNA-3 expres-
sion plasmid (Invitrogen).
Cell transfection
Mouse promyelocytic 32Dcl.3 cells were stably transfected
with pcDNA3 empty vector or pcDNA3-encoding active
Mas-BXB or pcDNA-3-encoding inactive Mas-BXB K375W
as previously described [3]. 293 cells were transiently
transfected by a calcium phosphate method with pTracer-
CMV-encoding HA-VDAC1 and/or pcDNA3 encoding C-
Raf.
Figure 7
VDAC function is unaffected by active PAK1 or Lck kinase. As a negative control VDAC was pre-incubated with active His-PAK1-
T423E or active His-LckY505F recombinant proteins (C). The aqueous phase contained 0.3 M KCl and the applied membrane
potential was 20 mV.BMC Cell Biology 2002, 3 http://www.biomedcentral.com/1471-2121/3/14
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Flow cytometry
For FACS analysis 32Dcl.3 cells lines were maintained in
IL-3 deprived RPMI medium with 10% serum for 24 h.
Cells were incubated with 7,5 µg/ml JC-1 for 15 min at
room temperature, washed with PBS and subjected to
FACS analysis.
Cell fractionation and immunoblotting
32Dcl.3 cells and transfectants were maintained in IL-3
deprived RPMI complete medium for 12 to 24 h. Cells
were washed three times in phosphate-buffered saline so-
lution and frozen at -70°C. Cell pellets were homogenized
in buffer (10 mM Hepes pH 7. 4, 0,3 M mannitol, 1 mM
EGTA) containing protease inhibitors and centrifuged two
times at 600 g for 5 minutes at 4°C. After a further centrif-
ugation at 12 000 ×  g for 15 minutes at 4°C, cell pellets
contained-mitochondria enriched fraction were solubi-
lised in the same buffer and a cytosolic fraction was ob-
tained after centrifugation at 100000 ×  g for 1 h at 4°C.
Proteins were resuspended in Laemmli buffer, applied to
SDS-PAGE, transferred to a nitrocellulose membrane and
analysed as described previously [6].
Immunoprecipitation
48 hours after transfection cells were lysed in NP-40 buffer
(10 mM Hepes pH 7.4, 145 mM KCl, 5 mM MgCl2, 1 mM
EGTA, 0,5 % NP-40) containing protease inhibitors. After
centrifugation cell lysates were successively incubated
with anti-hemagglutinin antibody (12CA5) or anti-C-Raf
antibody and with protein A/G agarose beads. Immuno-
precipitates were washed with NP-40 buffer, resuspended
in Laemmli buffer and separated by SDS-PAGE. The pro-
Figure 8
C-Raf blocks VDAC reconstitution into membranes. Membrane conductance as a function of time after the addition of 50 ng/ml
VDAC (full squares) and 50 ng/ml VDAC pre-incubated with 150 ng/ml GST-C-RafDD (full points) to DiphPC membranes
(left-hand side arrow). The aqueous phase contained 300 mM KCl supplemented with kinase buffer. 15 minutes after addition
of VDAC, when the conductance was stationary 150 ng/ml GST-C-RafDD was added to both sides of the membrane (full
squares, right-hand side arrow). The temperature was 20°C and the applied voltage was 20 mV. Note that the membrane con-
ductance increase was inhibited when VDAC was preincubated with GST-C-RafDD (full squares), while this protein had no
influence on already existing channels (full points).BMC Cell Biology 2002, 3 http://www.biomedcentral.com/1471-2121/3/14
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teins were transferred to a nitrocellulose membrane and
analysed as described previously [6].
Kinase assay
HA-VDAC was immunoprecipitated from transfected 293
cells and incubated with GST-C-Raf recombinant proteins
in kinase buffer (25 mM Hepes, pH 7,4, 150 mM NaCl, 25
mM β -glycerophosphate, 1 mM DTT, 10 mM MgCl2) con-
taining 50 µM ATP and 10 µCi [32P]-γ  ATP. Alternatively,
GST-C-Raf was incubated with MEK as substrate instead of
HA-VDAC. Phosphorylation of HA-VDAC or MEK was an-
alysed by autoradiography. For the in vivo kinase assay
transfected 293 cells were grown in DMEM medium with
0,3% serum for 24 h. Cells were cultured in phosphate
free medium in the presence of 0,75 mCi [32P] for 2 h be-
fore HA-VDAC immunoprecipitation.
Protein purification
GST-C-RafYY340/341DD, GST-C-RafK375W, His-PAK1-
T423E and His-LckY505F were produced in Sf9 insect cells
and purified as described [3]. Escherichia coli BL21
DE3(pLysS) were transformed with pGEX plasmids. After
induction with isopropyl-β -D-thiogalactopyranoside
(IPTG) GST-Bcl-2∆ Tm protein was prepared from the bac-
terial soluble fraction incubated with glutathione-sepha-
rose. To remove the GST-tag from Bcl-2∆ Tm protein,
beads were washed with lysis buffer (50 mM Tris, pH 8, 1
mM EDTA, 10 mM β -mercaptoethanol) containing 0,1 %
Triton-X100 and 300 mM NaCl and incubated overnight
at 4°C in buffer (50 mM Tris pH 8, 20 mM β -mercaptoeth-
anol) containing thrombin (Sigma). Cleaved Bcl-2∆ Tm
was further purified on anion exchange Resource Q col-
umn (Pharmacia-Amersham) and the protein was eluted
in a NaCl gradient. VDAC was purified from rat liver as de-
scribed [33].
Lipid bilayer experiments
The channel-forming proteins were reconstituted into ar-
tificial lipid bilayer membranes in a teflon chamber
[21,28]. The membrane was formed from a 1% (w/v) so-
lution of diphytanoylphosphatidylcholine (DiphPC)
(Avanti Polar Lipids, Alabaster, AL) in n-decane. VDAC or
Bcl-2∆ Tm proteins were added to the KCl buffer in both
compartments of the chamber and the single-channel
conductance of the pores was measured after application
of a fixed membrane potential. To test the effect of C-Raf
kinase on VDAC or Bcl-2∆ Tm-formed channels, GST-C-
RafYY340/341DD, GST-C-RafK375W or GST alone were
incubated with channel-forming proteins in kinase buffer
in presence of ATP for 30 min at 30°C. Samples were ap-
plied on both sides of the DiphPC membrane in KCl buff-
er and single-channel formation was measured. As a
control GST, GST-C-RafYY340/341DD and GST-C-
RafK375W were checked to not be able to form channels
in artificial bilayer membranes. In control experiments
VDAC was first added to an artificial membrane. After re-
constitution of several channels active and inactive C-Raf
were added to the aqueous phase and their effect on
VDAC was investigated.
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